AstraZeneca PLCAZN:LSE

3,850.5
77.50 / 1.97%
1.54m
13.69 %
0.6247
Latest price in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of May 03 2016 11:28 BST.

Consensus recommendation

As of Apr 29, 2016, the consensus forecast amongst 34 polled investment analysts covering AstraZeneca plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Jan 20, 2016. The previous consensus forecast advised investors to hold their position in AstraZeneca plc.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy7
Outperform11
Hold13
Underperform2
Sell0
No opinion0

Share price forecast

Share price forecast information is not available for AstraZeneca PLC. View Full Financials

Dividends

In 2015, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 28 analysts covering the company expect dividends of 2.79 USD for the upcoming fiscal year, maintaining dividends from this year. View Full Financials

Div growth (TTM)0.00%
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Apr 29, 2016, AstraZeneca plc reported 1st quarter 2016 earnings of 0.95 per share. This result was in line with the consensus of the 17 analysts following the company and under-performed last year's 1st quarter results by 12.04 %.
The next earnings announcement is expected on Jul 28, 2016. View Full Interim Financials

Average growth rate-2.68 %

AstraZeneca plc reported annual 2015 earnings of 4.26 per share on Feb 04, 2016. View Full Annual Financials

Average growth rate-12.22 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

AstraZeneca PLC had 1st quarter 2016 revenues of 6.12bn. This bettered the 5.96bn consensus of the 16 analysts covering the company. This was 0.96% above the prior year's 1st quarter results. View Full Interim Financials

Average growth rate+0.33 %

AstraZeneca PLC had revenues for the full year 2015 of 23.64bn. This was 9.40 % below the prior year's results. View Full Annual Financials

Average growth rate-8.18 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.